Insilico Medicine appoints Dr. Feng Ren as co-CEO

Dr. Ren is currently the Scientific Director of Insilico Medicine and the Director of Global Research and Development. He will retain these titles after his appointment and will also oversee clinical development with full control over discovery, development and infrastructure. In addition, he will further drive Insilico’s business development in his new role. This appointment reinforces Insilico’s commitment to artificial intelligence and drug development. Alex ZhavoronkovPh.D., will continue to serve as CEO and focus on global expansion and next-generation AI platforms, while Dr. Ren will lead the company’s drug development efforts.

After earning a Ph.D. in organic chemistry Harvard University, Dr. Ren spent 15 years in drug discovery and development in the healthcare industry, including working for a large multinational pharmaceutical company and a global contract research organization (CRO). He joined Insilico Medicine from Medicilon, a global CRO, where he served as Senior Vice President and Head of Drug R&D, leading the Chemistry and Biology departments. Prior to joining Medicilon, Dr. Ren held various leadership positions in drug discovery at GlaxoSmithKline (GSK) in both philadelphia cream and Shanghai.

He advised Insilico before joining the company, assessing the potential of its end-to-end biology and chemistry AI platform. In February 2021Dr. Ren became Scientific Director of Insilico, overseeing internal drug discovery efforts, and helped Insilico deliver the first AI-discovered new target and AI-designed novel molecule in studies enabling the IND.

“I’m excited to find new solutions to accelerate and improve drug discovery. As an advisor, I’ve seen Insilico harness the potential of AI in new ways,” said Feng RenPh.D., Co-CEO and CSO of Insilico Medicine. “What impressed me the most was that the team led by Alex had years of experience in solving pharmaceutical problems. I recognized a company ready to discover new therapies at scale and with great efficiency. It was an incredible opportunity, so I was very happy to take the plunge and move to AIDS.”

Under Dr. Ren’s leadership, Insilico has expanded the drug discovery team and developed a growing portfolio in frontier regions. Since 2021, the company has nominated 8 preclinical and advanced candidates in studies enabling IND, including with a novel protease inhibitor 3CL for the treatment of COVID-19, and two synthetic lethality programs targeting MAT2A and USP1 for indications in oncology. It has also successfully completed a Phase 0 microdose study and entered a Phase I clinical trial with its first in-house developed program targeting fibrosis. Dr. Ren has also contributed significantly to corporate strategies, business development, and geographic site operations.

“Dr. Ren is a phenomenal leader and innovator, and I’m thrilled to take Insilico Medicine to the next level with him as co-captain,” said Alex ZhavoronkovPhD., Founder and CEO of Insilico Medicine. “Since Dr. Ren joined the company, we have set several industry records. We never imagined how quickly we would advance our drug candidate with a novel target and molecule discovered and engineered using Insilico’s proprietary AI in the clinic Dr. Ren and I are ready to follow this first success with many others.

The company has innovated in a number of areas, including developing a discovery model in which multiple CROs perform redundant experiments to ensure data is validated. Under Dr. Ren’s leadership, Insilico has also assembled a discovery team in the same time zone as the CROs. Additionally, the company recently announced a fully automated AI-driven robotics lab to be launched later this year.

“We are at a pivotal moment. We have a clinical program, and we hope that many more programs will soon reach the clinical stage. We are also in the process of setting up a fully automated AI-driven robotics laboratory, a technology to accelerate our drug R&D,” said Feng RenPh.D., Co-CEO and CSO of Insilico Medicine. “To grow, we are building an innovative new organizational structure with many individual and team contributors who drive innovation with passion, dedication and the highest level of operational excellence. Simultaneously, we continue to focus on growth and advancing our proprietary AI platform. I am excited to serve as co-CEO and look forward to taking the company to the next level, delivering on our commitment to accelerate drug discovery and development and contribute to the unmet medical needs of patients around the world”.

About Insilico Medicine

Insilico Medicine, an end-to-end clinical-stage artificial intelligence (AI)-focused drug discovery company, connects clinical trial biology, chemistry and analytics using novel AI systems. generation. The company has developed AI platforms that use deep generative models, reinforcement learning, transformers and other modern machine learning techniques to discover new targets and design new molecular structures with desired properties. Insilico Medicine offers breakthrough solutions to discover and develop innovative drugs against cancer, fibrosis, immunity, central nervous system (CNS) diseases and age-related diseases.

More information on

For media inquiries, please contact [email protected]

Photo –
Photo –

SOURCE Insilico Medicine

Comments are closed.